Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $15.
September 30, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for Inozyme Pharma and maintained a $15 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $15 price target by a reputable analyst suggests a positive outlook for Inozyme Pharma. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100